Delivery of vaccine antigens to the dermis and/or epidermis of human skin (i.e. intradermal delivery) might be more efficient than injection into the muscle or subcutaneous tissue, thereby reducing the volumes of antigen. This is known as dose-sparing and has been demonstrated in clinical trials with some, but not all, vaccines. Dose-sparing could be beneficial to immunization programmes by potentially reducing the costs of purchase, distribution and storage of vaccines; increasing vaccine availability and effectiveness. The data obtained with intradermal delivery of some vaccines are encouraging and warrant further study and development; however significant gaps in knowledge and operational challenges such as reformulation, optimizing vaccine presentation and development of novel devices to aid intradermal vaccine delivery need to be addressed. Modelling of the costs and potential savings resulting from intradermal delivery should be done to provide realistic expectations of the potential benefits and to support cases for investment. Implementation and uptake of intradermal vaccine delivery requires further research and development, which depends upon collaboration between multiple stakeholders in the field of vaccination.
2 For some vaccines, there has been a clear demonstration of dose-sparing by intradermal delivery; however, there are several gaps in knowledge as well as developmental and operational challenges to overcome if the benefits of using intradermal delivery are to be fully realized.
Potential benefits
Dose-sparing arising from intradermal delivery of vaccines could be beneficial to immunization programmes, particularly in resource-poor settings, by potentially reducing the per-injection cost (including transport and storage) of vaccines because more doses might be obtained from the existing vaccine presentation.
Dose-sparing might also "stretch" the availability of vaccines in cases where supply is limited by manufacturing capacity. This is probably most relevant for pandemic influenza vaccines where global production capacity limits access to a vaccine at the start of a pandemic. 3 In 2009, H1N1 vaccine was not available in most low-income countries until 8 months after WHO's declaration of the influenza pandemic. 4 Other vaccines with potential supply constraints include yellow fever and inactivated poliovirus vaccines. 5, 6 The level of demand for inactivated poliovirus vaccine in the period following eradication of wild-type polioviruses and the end of the use of oral poliovirus vaccines is uncertain, but modelling suggests that there could be a "demand spike" and supply shortage of inactivated poliovirus vaccine during this period.
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New delivery devices
New devices for easier, more reliable intradermal delivery as alternatives to the currently 
Recent vaccine approvals
A new presentation of a split, trivalent seasonal influenza vaccine, Intanza ® (sanofi pasteur, Lyon, France) has been developed for intradermal immunization. The vaccine is delivered using the Soluvia device, a prefilled syringe with a single needle that is 1.5 mm in length. 19, 20 Immune responses equivalent to those induced by the standard regimen can be achieved using this device and 60% of the standard dose of influenza vaccine. 21, 22 A reduced-dose formulation (9-µg haemagglutinin rather than the standard 15-µg haemagglutinin) for use in healthy adults and a 15-µg haemagglutinin formulation for intradermal delivery in adults aged  60 years have been approved in Australia, Europe and New Zealand.
23-25
Knowledge gaps only to determine whether reduced intradermal doses were able to induce a sufficient or non-inferior immune response compared with the standard regimen. In these cases it is possible that a reduced dose delivered by the standard route would also have resulted in an equivalent immune response, as has been reported with some influenza vaccines. 26, 27 Furthermore, the majority of dose-sparing trials have for reasons of practical simplicity delivered 10% or 20% of the standard dose intradermally. Finer dose-titrations such as Publication: Bulletin of the World Health Organization; Type: Policy and Practice Article ID: BLT.10.079426
Page 5 of 14 those performed with influenza vaccines have shown that less-dramatic reductions in dose, such as a 40% reduction, might be more realistic. 22 To address these concerns, future studies should compare equivalent antigen doses given by the intradermal and standard route and, if possible, establish a dose-response relationship to determine whether any dose-sparing effect observed is simply due to using doses of antigen from the plateau-portion of the dose-response curve.
Which vaccines?
For any vaccine, the drivers for changing to the intradermal route, such as the need for dose-sparing to reduce costs and "stretch" the available manufacturing capacity, have to be assessed, but the suitability of the vaccine type and formulation for administration by this route also need to be considered. This example reinforces the point that the cost of manufacturing a vaccine is only a proportion of the overall cost of delivering each dose; furthermore, vaccine manufacturers will not necessarily pass on the full savings arising from a reduction in antigen content per dose. Novel devices for intradermal delivery are likely to be more expensive than needles and syringes, and immunization programmes using new devices will also incur the costs of retraining health workers.
A major benefit of changing to needle-free devices is a reduction in the direct health-care and societal costs resulting from needlestick injuries, although this is difficult to quantify in financial terms. 8, 31 A reduction in the use of sharps and their associated costs could also be achieved, possibly more easily, by using needle-free delivery devices such as disposable-syringe jet injectors, without changing the route or dose of vaccine administered.
The incremental costs associated with changing some routine childhood vaccinations in Brazil, India and South Africa to intradermal delivery of reduced (20%) doses have been modelled. 32 For India and South Africa, the model indicated that In applications where it is warranted, significant investment by vaccine manufacturers and other stakeholders will be required to change the route of vaccine delivery. It is important, therefore, to model accurately the costs involved to determine the potential benefits and to support the case for investment. Decisions should be based on cost modelling and economic analysis, with continual improvement of inputs and assumptions.
Challenges
Changing the delivery route and dose for a vaccine is not a straightforward task, and several challenges and operational issues need to be addressed.
Demonstration of efficacy
The applicability and benefits of intradermal administration will vary among vaccines; it cannot be assumed that reduced intradermal doses will be efficacious in all cases. Even when there is dose-sparing, it might not be with a dose as low as 20% or 10% of the standard dose. The degree of dose-sparing that can be achieved will need to be Publication: Bulletin of the World Health Organization; Type: Policy and Practice Article ID: BLT.10.079426
Page 8 of 14 determined for each vaccine in non-inferiority trials. It will also be important to maintain a "margin of safety" to ensure adequate immunogenicity across the whole target population and to ensure the potency of the reduced dose is sufficient to induce protection at the end of the vaccine's shelf life.
Reformulation
Intradermal doses of 20% of a standard 0.5 ml dose or 10% of a 1.0 ml dose might not require reformulation; 0.1 ml of the existing formulation could easily be administered, as is the usual practice in clinical trials of intradermal delivery. If more antigen per dose is required, then the vaccine will need to be concentrated so that it can be delivered in the smaller volume. In the development of Intanza ® , which contains 60% of the standard amount of antigen in 20% of the volume, there were challenges filling the device with a small volume as well as adjusting vaccine concentration and viscosity. 34 Even if there is no need to adjust the concentration of the vaccine, it might be necessary to incorporate a preservative into the formulation if dose-sparing means that more than one dose can be obtained per vial.
Vaccine presentation
One consequence of delivering a smaller volume per dose is that a single-dose vial 
Regulatory issues
Intradermal delivery of fractional doses of an existing vaccine formulation intended for subcutaneous/intramuscular injection would have to be undertaken on an "off-label" basis. A licensing amendment between the relevant national regulatory authority and the vaccine producer would be needed to authorize official "on-label" use of fractional doses. 37 Alternatively, marketing approval for the new intradermal formulation and presentation of the vaccine would be needed. Research and development in all of these disciplines is required if the promise of intradermal delivery is to be realized; this will require collaboration between academic and clinical researchers, vaccine manufacturers, device developers, regulatory authorities, national immunization programmes and nongovernmental global health organizations. A careful evaluation of all aspects of this route of delivery for vaccines should continue to be a priority for global public health.
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